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Objectives. We sought o investigate he role of polymorphisms 
of the gene for angiotensin-converting e zyme in the development 
and progression of idiopathic dilated cardiomyopathy. 
Background. Cardiovascular renin-angiotensin ystems may be 
involved in cardiac remodeling and fibrosis. The absence (deletion 
[D]) of a 287-base pair marker in the angiotensin-converting enzyme 
gene (intron 16) is associated with increased serum angiotensin- 
converting enzyme l vels. The DD genotype may be a risk factor for 
the development of end-stage heart failure due to cardiomyopathy. 
We therefore xamined the relation of the angiotensin-converting 
enzyme genotype toidiopathic dilated cardiomyopathy and to mark- 
ers of disease severity. 
Methods. We studied 364 control subjects and 99 consecutive 
patients with idiopathic dilated cardiomyopathy. When the inci- 
dence of the DD genotype inour control group was assumed to be 
similar to that previously reported (27%), this study had a power 
of 0.9 to detect a different incidence in the patient group, if the 
true incidence in patients was 42%. Deoxyribonucleic acid (DNA) 
was isolated from blood samples, and angiotensin-converting 
enzyme genotype was determined by specific polymerase chain 
reaction and separation of amplified fragments by agarose gel 
electrophoresis. We also compared genotype distribution with that 
in previously reported European control subjects. Functional 
status, clinical course over a mean -+ SD of 28 + 33 months and 
outcome were documented. Cardiac morphology and function and 
evidence of rhythm disturbance were noninvasively determined. 
Results. Angiotensin-converting e zyme genotype distribution 
and allele frequencies were similar in patients and control sub- 
jects to within 10% (with 95% confidence) and were also similar 
between patients and European control subjects. No markers of 
disease severity or progression other than duration of symptoms 
before diagnosis and the number of ventricular ectopic beats/h 
were significantly associated with the presence of the DD alleles. 
Conclusions. We find no evidence to support an association 
between angiotensin-converting e zyme genotype and either the 
diagnosis of idiopathic dilated cardiomyopathy itself or progres- 
sion of the disease. 
(J Am CoU Cardio11995;25:1627-31) 
Systemic or local cardiovascular renin-angiotensin ystems may 
be involved in cardiac remodeling and fibrosis (1-3). In formal 
segregation analysis tudies, the absence (deletion [D]) rather 
than the presence (insertion [I]) of a 287-base pair marker in 
the angiotensin-converting e zyme gene (intron 16) has been 
shown (4) to be associated with raised serum levels of the 
enzyme responsible for the conversion of angiotensin I to 
angiotensin II. Furthermore, the deletion polymorphism has 
been reported to be a risk factor for the development of 
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myocardial infarction (5,6). Against his background, Raynolds 
et al. (7) reported that possession of the angiotensin- 
converting enzyme DD genotype was a risk factor for the 
development of end-stage heart failure due to cardiomyopathy. 
However, their conclusion has been questioned. The allele 
frequencies were similar in both the case and control group in 
their study. Their control group data were not in Hardy- 
Weinberg equilibrium, as there were fewer patients with the 
DD and II genotypes than either expected (8) or previously 
reported (5,9). The use of a small control group composed of 
young potential organ donors and genetic heterogeneity 
among both the patient and control groups were additional 
limitations of their study. The involvement of the angiotensin- 
converting enzyme genotype in the genesis of idiopathic di- 
lated cardiomyopathy as opposed to its progression was not 
directly addressed. We therefore determined the angiotensin- 
converting enzyme genotype in 99 consecutive patients with 
well characterized idiopathic dilated cardiomyopathy referred 
for management of heart failure and in 364 control subjects. 
The relations among genotype, the diagnosis of idiopathic 
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dilated cardiomyopathy itself and markers of disease severity 
and clinical progression of the disease were examined. 
Methods  
This study was performed with hospital ethical committee 
approval. No patients were subjected to invasive investigation 
unless the procedure was clinically indicated. All gave written 
informed consent. 
Patients. The diagnosis of idiopathic dilated cardiomyop- 
athy was based on the criteria recommended by the World 
Health Organization and the National Heart, Lung, and Blood 
Institute (10). All patients had left ventricular dilation (end- 
diastolic diameter >2.7 cm/m 2) (11) and impaired systolic 
contraction (left ventricular ejection fraction <40% or frac- 
tional shortening <25%). Patients with ->50% obstruction of 
one or more coronary arteries, active myocarditis (12), specific 
primary or secondary heart muscle disease, sustained systemic 
arterial hypertension, isolated right ventricular dilation and 
valvular or pericardial disease were excluded. Twenty-seven 
patients with a history of chronic excess alcohol consumption 
(>8 U/day for male patients and >6 U/day for female patients) 
were included. 
We studied 99 consecutive unrelated white patients with 
idiopathic dilated cardiomyopathy (mean age _+ SD 41 _+ 
14 years [range 12 to 73]; 79 male) who presented to St. 
Georges Hospital between January 1989 and March 1994. 
Functional assessment a  presentation demonstrated that 42 
were in New York Heart Association class I, 17 in class II, 25 
in class III and 15 in class IV when first seen. They were 
assessed by 12-lead electrocardiography, chest radiography, 
two-dimensional transthoracic Doppler echocardiography, 
24-h ambulatory electrocardiographic (ECG) monitoring, ra- 
dionucleotide v ntriculography and maximal symptom-limited 
exercise testing. M-mode guided short-axis views at the level of 
the papillary muscles were used to assess left ventricular cavity 
dimensions. Cardiac catheterization with selective coronary 
angiography was performed in 81 patients. The remaining 18 
patients were all <40 years old with no risk factors for ischemic 
heart disease and no evidence of ischemia on exercise ECG 
testing. Endomyocardial biopsy in the 56 patients who con- 
sented to the procedure was normal in 23 and showed fibrosis 
in 33. The clinical and demographic characteristics of those 
consenting tobiopsy and those who declined were similar. The 
left ventricular ejection fraction at diagnosis was 25 + 11% and 
left ventricular end-diastolic volume 68 _+ 11 mm 3. Duration of 
symptoms was defined empirically as the time from first 
reported symptoms to time of first confirmation ofdiagnosis of 
idiopathic dilated cardiomyopathy recorded in the case notes. 
Patients were followed up for a mean of 28 _+ 33 months. 
During this period 35 patients howed clinical deterioration, 
including 22 who required heart ransplantation. I  addition, 
four patients had a sudden cardiac death (13). 
Control groups. The study control group consisted of 364 
white men (mean age 54 +_ 3 years [range 49 to 60]) drawn 
from a local general practice group. Subjects With symptoms 
Table 1. Distribution ofthe Deletion (D)/Insertion (I)
Polymorphism of the Gene for Angiotensin-Converting 
Enzyme in the Patients and Control Subjects 
Allele 
Genotype Frequency 
DD ID II D I 
Patients 31 (31%) 50 (51%) 18 (18%) 0.57 0.43 
Control subjects 
Present study 112 (31%) 168 (46%) 84 (23%) 0.54 0.46 
ECTIM study 200 (27%) 390 (53%) 143 (20%) 0.53 0.47 
Genotypc data are presented as number (%) of patients. ECTIM = Etude 
Cas-Temoins sur l'Infarctus du Myocarde. 
suggestive ofcoronary artery disease or with a known diagnosis 
of ischemic heart disease were excluded. We also compared 
our patients with the previously reported European control 
sample from the Etude Cas-Temoins ur l'Infarctus du Myo- 
carde (ECTIM) study (5). 
Deoxyribonucleic acid extraction and genotyping the 
angiotensin-converting enzyme I/D polymorphism. We iso- 
lated DNA from 5-ml blood samples using the "salting out" 
procedure (14). Detection of the I/D polymorphism in intron 
16 of the angiotensin-converting e zyme gene used polymerase 
chain reaction amplification, as previously described (4), with 
subsequent separation of the fragments by agarose gel 
electrophoresis. 
Statistics. We assumed that the frequency of the DD 
genotype in our control subjects would be similar to that 
previously reported (27%) (5). Given 99 patients and 364 
control subjects, this gave the study a power of 0.9 to detect a
different incidence in the patient group of 42%. Differences in 
the distribution of the DD, DI and II genotypes were assessed 
by contingency table/chi-square analysis. Numeric data be- 
tween different groups were compared by using unpaired 
two-tailed t tests, and outcomes were compared by a one-tailed 
analysis of variance test. All p values were expressed with 
continuity corrections. A p value < 0.05 was considered 
statistically significant. 
Results 
We compared angiotensin-converting enzyme genotype/ 
allele frequencies in our patient, our control and previously 
reported healthy European control (5) groups (Table 1). Allele 
frequencies in the control and patient groups were consistent 
with Hardy-Weinberg equilibrium. The genotype distribution 
in the control group fit well with that previously reported (p = 
0.1 [5]: p > 0.1 [9]) and was similar to that in the patient group 
(p = 0.75). The DD genotype frequency was the same (within 
10%, with 95% confidence) between groups: the difference in 
DD genotype frequency between the patient and control groups 
was 0.005 (31/99 vs. 112/364: 95% confidence interval + 0.103). 
The same held true when the patient group was compared with 
European control subjects (p = 0.75). The allele frequencies in
the patient group were also not significantly different from those 
in the control groups (p = 0.5). The difference in D allele 
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Table 2. Characteristics of Patients With Dilated Cardiomyopathy According to Genotype for Angiotensin Deletion (D) or 
Insertion (I) Polymorphism 
Genotype p Value 
DD ID II ID + II DD/II DD/Other 
Age (yr) 43 + 13 36 _+ 14 47 _+ 17 40 _+ 15 0.32 0.56 
Gender 
Male 27 41 11 52 
Female 4 9 7 16 0.08 0.34 
NYHA class 
I/II 17 33 9 42 
IIIflV t4 17 9 26 0.98 0.67 
Duration (too) 
Follow-up 30 _+ 29 29 _+ 34 26 + 37 28 + 35 0.71 0.8 
Symptoms before diagnosis 50 _+ 52 29 + 34 26 -- 40 27 _+ 51 0.16 0.02 
Ejection fraction (n = 58) (%) 22 _+ 8 28 + 12 22 _+ 11 26 _+ 12 0.93 0.2 
Left ventricular end-diastolic dimension (n 77) (mm) 72 _+ 12 65 -+ 9 72 +_ 12 67 -+ 10 0.96 0.51 
• Left ventricular f actional shortening (n = 77) (%) 14 _+ 6 15 _+ 7 14 _+ 7 14 _+ 7 0.91 > 0.9 
Pulmonary artery wedge pressure (n = 45) (mm Hg) 20 _+ 11 18 _+ 7 28 -+ 7 20 _+ 8 0.095 0.78 
Ventricular ecotopic beats (n = 48) (beats/h) 333 _+ 334 143 + 294 81 _+ 134 128 _+ 264 0.06 0.03 
Nonsustained ventricular tachycardia 
Patients with 11 12 5 17 
Patients without 7 18 6 24 0.66 0.27 
Fibrosis on endomyocardial biopsy 
Patients with 14 13 6 19 
Patients without 7 13 3 16 0.67 0.53 
Data are expressed as mean value _+ SD or number of patients. NYHA class = New York Heart Association functional class; other abbreviations a in Table 1. 
frequency was negligible (0.027 _+ 0.078), being within 10% with 
95% confidence. 
In the patient group, the relation between angiotensin- 
converting enzyme genotype and clinical markers of disease 
severity and progression were examined (Tables 2 and 3). 
Patients with the DD genotype (n = 31) were compared with 
patients homozygous for the I allele (n = 18) and with the total 
group of "non-DD" (ID and II: n = 68) patients. The age and 
gender characteristics of these groups were similar. Only the 
duration of symptoms before diagnosis and the number of 
ventricular ectopic beats/h were significantly associated with 
the presence of the DD alleles, with patients homozygous for 
the D allele having the longer duration of symptoms and the 
greater number of ventricular ectopic beats/h. In particular, 
the presence of fibrosis at endomyocardial biopsy was not 
associated with the DD genotype, and the incidence of fibrosis 
was similar in patients with different genotypes. Genotype 
distribution and allele frequency were similar in patients who 
had progressive heart failure or required orthotopic heart 
transplantation when values were compared with those in the 
Table 3. Progresssion f Disease in Patients With Dilated 
Cardiomyopathy, According to Angiotensin-Converting E zyme 
Gene Deletion (D) or Insertion (I) Polymorphism 
DD ID II 
Progressive heart failure or heart ransplantation 12 15 8 
Sudden cardiac death 0 3 1 
Clinically stable condition 19 32 9 
Abbreviations as in Table 1. 
clinically stable patients (p = 0.5), the European control group 
(p = 0.5) or our control group (p > 0.5). 
Discuss ion 
Systemic and paracrine renin-angiotensin systems. Physi- 
ologically and pathophysiologically modulated expressions 
(15-18) of renin-angiotensin system components and messen- 
ger ribonucleic acids have been identified in cardiovascular 
tissues including the heart (19-21). Cardiac renin-angiotensin 
systems may thus have an autocrine/paracrine function that 
may influence cardiac architecture, growth and function and 
through which the action of angiotensin-converting enzyme 
inhibitors may be partly mediated (15,22-24). 
Potential role of renin-angiotensin systems in eardiomyop- 
athy. Many findings suggest a potential role for this system in 
cardiomyopathic processes. Components such as angiotensin II 
activity may damage myocytes, causing increased membrane 
permeability and microscopic scarring (25). Cultured rat fibro- 
blasts have functional angiotensin II receptors (26), and angio- 
tensin II increases collagen synthesis (27). Rat cardiac ollagen 
deposition may be regulated by renin-angiotensin system ac- 
tivity (1,28,29) and prevented by nonhypotensive doses of 
angiotensin-converting e zyme inhibitors (2,3) or angiotensin- 
converting enzyme inhibitor treatment after experimental 
myocardial infarction (30,31). 
Cardiac function and structure may also be influenced. An- 
giotensin II impairs my0cyte relaxation (32,33), and angiotensin- 
converting enzyme inhibition improves diastolic function in ani- 
mals (34) and the hypertensive human heart (35). 
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Angiotensin-converting enzyme genotype and dilated car- 
diomyopathy. Recently, a polymorphism of the gene for an- 
giotensin-converting enzyme has been discovered, consisting of 
the presence (insertion allele or "I") or absence (deletion 
allele or "D") of a 250-base pair fragment. This polymorphism 
is strongly associated with circulating (and possibly tissue) 
levels of the enzyme, with those of a DD genotype having 
highest levels (9). If renin-angiotensin ystem activity is asso- 
ciated with myocardial pathogenicity, then patients with the 
DD genotype might be expected to suffer most. 
Given these findings, an association between angiotensin- 
converting enzyme genotype and dilated cardiomyopathy 
would seem feasible. Raynolds et al. (7) compared 112 white 
patients with end-stage dilated cardiomyopathy, of whom 93 
required heart ransplantation, with 79 younger white control 
subjects and found that the frequency of the DD genotype was 
36% in patients and 24% in control subjects (p < 0.01). 
However, an associated excess of the II genotype counters the 
concept hat DD genotype xerts a pathophysiologic a tion 
through associated raised levels of angiotensin-converting e -
zyme actMty. Further, they did not examine the association of 
angiotensin-converting enzyme gene polymorphism with the 
diagnosis of dilated cardiomyopathy itself, or with disease 
severity or progression of disease within a cohort. Our study 
has addressed these issues. 
The DD genotype is only strongly associated with myocar- 
dial infarction in an otherwise low risk group in which only 
35% of cases might be ascribed to its possession (5). Distortion 
of allele distribution i our control group due to the presence 
of, or mortality from, ischemic heart disease can therefore be 
only minimal. Similarly, idiopathic dilated cardiomyopathy is 
uncommon, and undiagnosed control cases are unlikely to 
introduce significant bias. 
Our results demonstrate no association between angiotensin- 
converting enzyme genotype or allele frequencies and a diagnosis 
as such of idiopathic dilated cardiomyopathy or biopsy-proved 
myocardial fibrosis among patients. The D allele is slightly (but 
not statistically significantly, p = 0.5) more common among 
patients than among control subjects. However, like the study 
by Raynolds et al. (7), our study would have lacked the power 
to detect a small increase in relative risk associated with the 
presence of the D allele. 
We also examined the association Of polymorphism with 
progression ofdisease by comparing clinical variables in patients 
with the DD genotype (n = 31) with those in patients in the II (n 
= 18) and non-DD groups (II and ID: n = 68) (Table 2). The 
association between DD genotype and increased time to diagno- 
sis suggests, if anything, that patients with a DD genotype had 
slower progression of disease, because clinical grading of symp- 
toms at presentation and all measures of ventricular contractility 
were similar irrespective ofpatient genotype. However, "time to 
diagnosis" (first recalled symptoms tofirst recorded iagnosis) is
an empiric measure subject o various social, personal, profes- 
sional and pathologic nfluences. 
The frequency of the DD genotype and D allele was similar 
in the 35 patients with progressive disease (including the 4 
patients who died suddenly) and in the 60 patients with a stable 
course. However, the risk of end-stage idiopathic dilated 
cardiomyopathy previously attributed tohaving two D alleles is 
small (odds ratio 1.43), and these numbers may be insufficient 
to rule out such a weak association of the angiotensin- 
converting enzyme genotype with progression to end-stage 
heart failure. 
Our results do accord with some features of the study of 
Raynolds et al. (7). The frequency of the D allele in their 
patient and control groups (M. Raynolds, personal communi- 
cation, February 1994) and in our patient group was remark- 
ably similar (D frequency 0.56, 0.57, 0.57, respectively.) 
Our failure to demonstrate any association between the 
gene polymorphism and the diagnosis of idiopathic dilated 
cardiomyopathy as such may be due to several factors. There 
are theoretic difficulties in population studies uch as these in 
determining what makes an association (or lack of it) signifi- 
cant, and there are pitfalls in applying the investigational 
standards derived for Mendelian traits to studies of more 
complex phenotypes ordiseases (36). Differences in patient or 
control characteristics may also have played a role: The two 
groups of patients studied were different, the group of 
Raynolds et al. (7) comprising those with end-stage disease of 
undefined etiology and characteristics on the one hand, and 
our well characterized unrelated probands with various levels 
of disease severity on the other. The control groups also 
differed. Ours was drawn from a local general practice popu- 
lation and was slightly older than our patient group (mean + 
SD 54 _+ 3 vs. 41 _+ 14 years). Theirs largely comprised 
potential heart donors and the subjects were younger (mean + 
SEM 33 + 1.8 vs. 44.8 + 1.5 years). The subjects in neither 
group had a proved normal heart. Ejection fractions as low as 
30% were accepted as normal in their small (n = 79) control 
group, which itself did not obey the Hardy-Weinberg equilib- 
rium. The incidence of the II genotype (12.7%) was far lower 
than that previously reported (8) in control groups (19.5% [5] 
and 17.5% [9]). The frequency of the DD genotype (24%) was 
also lower than expected (8) or previously reported (36.25% 
[9] and 27% for ECTIM control subjects [5]). It is this unusual 
distribution of alleles among control subjects that accounts for 
much of the statistically significant excess of the DD genotype 
in their patient group over that of their control subjects. In 
contrast, our control group was much larger (n = 364), its data 
obeyed the Hardy-Weinberg equilibrium, and the genotype 
and allele frequencies were similar to those seen in a large 
(n = 733) European control sample (5). 
Raynolds et al. (37) correctly state that the issue under 
discussion is whether this genetic variant of the angiotensin- 
converting enzyme gene predisposes a person to the develop- 
ment of cardiomyopathy. Using similar numbers of patients, 
we found no evidence that it does. Neither do our data suggest 
a major role for the angiotensin-converting enzyme DD ge- 
notype in the progression of idiopathic dilated cardiomyopa- 
thy. A large long-term follow-up study is required if such 
associations of this angiotensin-converting e zyme gene poly- 
morphism are to be investigated further. 
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